SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3595-3602. Prepublished online as a Blood First Edition Paper on December 21, 2006; DOI 10.1182/blood-2006-07-034678. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-07-034678v1 109/8/3595    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hönig, M. Articles by Friedrich, W. Search for Related Content PubMed PubMed Citation Articles by Hönig, M. Articles by Friedrich, W. Related Collections Stem Cells in Hematology Clinical Trials and Observations Hematopoiesis Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications Manfred Hönig1, Michael H. Albert2, Ansgar Schulz1, Monika Sparber-Sauer1, Catharina Schütz1, Bernd Belohradsky2, Tayfun Güngör3, Markus T. Rojewski4, Harald Bode1, Ulrich Pannicke4, Dominique Lippold4, Klaus Schwarz4, Klaus-Michael Debatin1, Michael S. Hershfield5, and Wilhelm Friedrich1 1 Department of Pediatrics, University of Ulm, Germany; 2 Dr von Haunersches Kinderspital, Ludwig Maximilians University Munich, Germany; 3 Division of Immunology/Hematology/BMT, University Children's Hospital, Zürich, Switzerland; 4 Institute for Transfusion Medicine, University Hospital of Ulm and Institute for Clinical Transfusion Medicine and Immunogenetics, Ulm, Germany; 5 Duke Medical Center, Duke University, Durham, NC Adenosine deaminase (ADA) deficiency is a systemic metabolic disease that causes an autosomal recessive variant of severe combined immunodeficiency (SCID) and less consistently other complications including neurologic abnormalities. Hematopoietic stem cell transplantation (HSCT) is able to correct the immunodeficiency, whereas control of nonimmunologic complications has not been extensively explored. We applied HSCT in 15 ADA-deficient patients consecutively treated at our institutions since 1982 and analyzed long-term outcome. Seven patients received transplants without conditioning from HLA-matched family donors (MFDs); the other 8 patients received conditioning and were given transplants either from HLA-mismatched family donors (MMFDs; n = 6) or from matched unrelated donors (MUDs; n = 2). At a mean follow-up period of 12 years (range, 4-22 years), 12 patients are alive with stable and complete immune reconstitution (7 of 7 after MFD, 4 of 6 after MMFD, and 1 of 2 after MUD transplantation). Six of 12 surviving patients show marked neurologic abnormalities, which include mental retardation, motor dysfunction, and sensorineural hearing deficit. We were unable to identify disease or transplantation-related factors correlating with this divergent neurologic outcome. The high rate of neurologic abnormalities observed in long-term surviving patients with ADA deficiency indicates that HSCT commonly fails to control CNS complications in this metabolic disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020